MedStar Health, Columbia, MD 21044, USA.
Cancer Prevention & Control Program, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA.
Pharmacogenomics. 2023 Nov;24(16):859-870. doi: 10.2217/pgs-2023-0164. Epub 2023 Nov 9.
Identify oncology healthcare providers' attitudes toward barriers to and use cases for pharmacogenomic (PGx) testing and implications for prescribing anticancer and supportive care medications. A questionnaire was designed and disseminated to 71 practicing oncology providers across the MedStar Health System. 25 of 70 (36%) eligible oncology providers were included. 88% were aware of PGx testing and 72% believed PGx can improve care. Of providers who had ordered a medication with PGx implications in the past month, interest in PGx for anticancer (90-100%) and supportive care medications (>75%) was high. Providers with previous PGx education were more likely to have ordered a test (odds ratio: 7.9; 95% CI: 1.1-56; p = 0.0394). Oncology provider prescribing practices and interest in PGx suggest opportunities for implementation.
确定肿瘤学医疗保健提供者对药物基因组学 (PGx) 检测障碍和用例的态度，以及对开抗癌和支持性护理药物的影响。设计并向 MedStar 健康系统的 71 名执业肿瘤学提供者分发了一份问卷。70 名符合条件的肿瘤学提供者中有 25 名被纳入研究。88%的人了解 PGx 检测，72%的人认为 PGx 可以改善护理。在过去一个月内开具有 PGx 影响的药物的提供者中，对抗癌药物（90-100%）和支持性护理药物（>75%）的 PGx 非常感兴趣。有过 PGx 教育的提供者更有可能开测试（优势比：7.9；95%可信区间：1.1-56；p = 0.0394）。肿瘤学提供者的开处方做法和对 PGx 的兴趣表明了实施的机会。
Zotero 插件